Clinical Trials Logo

Stage IV Prostate Cancer clinical trials

View clinical trials related to Stage IV Prostate Cancer.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05189457 Recruiting - Prostate Cancer Clinical Trials

First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer

Start date: January 25, 2022
Phase: Phase 2
Study type: Interventional

The goal of this clinical research is to find if sequential therapy with combined androgen deprivation or hormonal therapy with luteinizing hormone release hormone (LHRH) analog plus a new hormonal agent (abiraterone, enzalutamide, or apalutamide) followed by chemohormonal therapy with docetaxel and LHRH analog would improve the outcome of high risk metastatic/stage IV prostate cancer.

NCT ID: NCT04113096 Recruiting - Clinical trials for Stage IV Breast Cancer

Dibenzyl Trisulphide (GUINEAHEN WEED) for Stage IV Cancer

Start date: October 1, 2018
Phase: Early Phase 1
Study type: Interventional

This study is being done to find the effect of Dibenzyl Trisulphide (active ingredient in Guinea Hen Weed in combination in patients with stage four cancer of the breast, prostate, cervix and colon.

NCT ID: NCT03880422 Recruiting - Obesity Clinical Trials

Nutrition and Exercise Interventions in Reducing Androgen Deprivation Therapy-Induced Obese Frailty in Prostate Cancer Survivors

Start date: May 2, 2019
Phase: N/A
Study type: Interventional

This trial studies how well nutrition and exercise interventions work in reducing androgen deprivation therapy-induced obese frailty in prostate cancer survivors. Individualized nutrition and exercise advice for prostate cancer patients on androgen deprivation therapy may help to reduce obese frailty and change the levels of myokines in blood.

NCT ID: NCT03016741 Recruiting - Clinical trials for Stage IV Prostate Cancer

Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer

Start date: March 31, 2017
Phase: Phase 4
Study type: Interventional

This clinical trial studies cognitive function in men with prostate cancer treated with androgen receptor directed therapies such as abiraterone acetate and enzalutamide. The investigators use MRI imaging (non-invasive, non-contrast) to see whether there are changes in brain structure or activity related to treatment that may be related to changes in cognitive function. The investigators are also looking for genetic variations that might make patients more or less sensitive to cognitive changes during treatment for prostate cancer.

NCT ID: NCT02935205 Recruiting - Clinical trials for Stage IV Prostate Cancer

Enzalutamide and Indomethacin in Treating Patients With Recurrent or Metastatic Hormone-Resistant Prostate Cancer

Start date: January 17, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial studies the side effects of enzalutamide and indomethacin and to see how well they work in treating patients with prostate cancer that does not respond to treatment with hormones, has come back, or has spread from where it started to other places in the body. Androgens can cause the growth of prostate cancer cells. Hormone therapy using enzalutamide and indomethacin may fight prostate cancer by lowering the amount of androgen the body makes and/or blocking the use of androgen by the tumor cells.

NCT ID: NCT02615223 Recruiting - Clinical trials for Stage IV Prostate Cancer

Endocrine Therapy With or Without Cryoablation for Stage IV Prostate Cancer

CRYO-PCA-IV
Start date: November 2015
Phase: N/A
Study type: Interventional

This trial is going to evaluate tumor control and quality of life in patients with prostate cancer treated with endocrine therapy with or without cryoablation.